Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
J Nucl Med. 2013 Oct;54(10):1768-74. doi: 10.2967/jnumed.112.113209. Epub 2013 Sep 5.
Hybrid PET/MR systems have recently entered clinical practice. Thus, the accuracy of MR-based attenuation correction in simultaneously acquired data can now be investigated. We assessed the accuracy of 4 methods of MR-based attenuation correction in lesions within soft tissue, bone, and MR susceptibility artifacts: 2 segmentation-based methods (SEG1, provided by the manufacturer, and SEG2, a method with atlas-based susceptibility artifact correction); an atlas- and pattern recognition-based method (AT&PR), which also used artifact correction; and a new method combining AT&PR and SEG2 (SEG2wBONE).
Attenuation maps were calculated for the PET/MR datasets of 10 patients acquired on a whole-body PET/MR system, allowing for simultaneous acquisition of PET and MR data. Eighty percent iso-contour volumes of interest were placed on lesions in soft tissue (n = 21), in bone (n = 20), near bone (n = 19), and within or near MR susceptibility artifacts (n = 9). Relative mean volume-of-interest differences were calculated with CT-based attenuation correction as a reference.
For soft-tissue lesions, none of the methods revealed a significant difference in PET standardized uptake value relative to CT-based attenuation correction (SEG1, -2.6% ± 5.8%; SEG2, -1.6% ± 4.9%; AT&PR, -4.7% ± 6.5%; SEG2wBONE, 0.2% ± 5.3%). For bone lesions, underestimation of PET standardized uptake values was found for all methods, with minimized error for the atlas-based approaches (SEG1, -16.1% ± 9.7%; SEG2, -11.0% ± 6.7%; AT&PR, -6.6% ± 5.0%; SEG2wBONE, -4.7% ± 4.4%). For lesions near bone, underestimations of lower magnitude were observed (SEG1, -12.0% ± 7.4%; SEG2, -9.2% ± 6.5%; AT&PR, -4.6% ± 7.8%; SEG2wBONE, -4.2% ± 6.2%). For lesions affected by MR susceptibility artifacts, quantification errors could be reduced using the atlas-based artifact correction (SEG1, -54.0% ± 38.4%; SEG2, -15.0% ± 12.2%; AT&PR, -4.1% ± 11.2%; SEG2wBONE, 0.6% ± 11.1%).
For soft-tissue lesions, none of the evaluated methods showed statistically significant errors. For bone lesions, significant underestimations of -16% and -11% occurred for methods in which bone tissue was ignored (SEG1 and SEG2). In the present attenuation correction schemes, uncorrected MR susceptibility artifacts typically result in reduced attenuation values, potentially leading to highly reduced PET standardized uptake values, rendering lesions indistinguishable from background. While AT&PR and SEG2wBONE show accurate results in both soft tissue and bone, SEG2wBONE uses a two-step approach for tissue classification, which increases the robustness of prediction and can be applied retrospectively if more precision in bone areas is needed.
探讨同时采集数据时基于 MR 的衰减校正的准确性。
对 10 例患者在全身 PET/MR 系统上采集的 PET/MR 数据集进行衰减图计算,允许同时采集 PET 和 MR 数据。在软组织(n=21)、骨(n=20)、骨旁(n=19)和 MR 磁敏感伪影内或旁(n=9)的病变中放置 80%等浓度体素的感兴趣区。以 CT 衰减校正为参考,计算相对平均感兴趣区差异。
在软组织病变中,与 CT 衰减校正相比,无一种方法的 PET 标准化摄取值出现显著差异(SEG1,-2.6%±5.8%;SEG2,-1.6%±4.9%;AT&PR,-4.7%±6.5%;SEG2wBONE,0.2%±5.3%)。在骨病变中,所有方法均低估了 PET 标准化摄取值,基于图谱的方法误差最小(SEG1,-16.1%±9.7%;SEG2,-11.0%±6.7%;AT&PR,-6.6%±5.0%;SEG2wBONE,-4.7%±4.4%)。在骨旁病变中,观察到较小程度的低估(SEG1,-12.0%±7.4%;SEG2,-9.2%±6.5%;AT&PR,-4.6%±7.8%;SEG2wBONE,-4.2%±6.2%)。对于受 MR 磁敏感伪影影响的病变,使用基于图谱的伪影校正可降低定量误差(SEG1,-54.0%±38.4%;SEG2,-15.0%±12.2%;AT&PR,-4.1%±11.2%;SEG2wBONE,0.6%±11.1%)。
在软组织病变中,没有一种方法显示出统计学上的显著误差。对于骨病变,忽略骨组织的方法(SEG1 和 SEG2)会导致 -16%和-11%的显著低估。在目前的衰减校正方案中,未校正的 MR 磁敏感伪影通常会导致衰减值降低,可能导致 PET 标准化摄取值大幅降低,使病变与背景难以区分。虽然 AT&PR 和 SEG2wBONE 在软组织和骨组织中都能得到准确的结果,但 SEG2wBONE 使用两步组织分类方法,增加了预测的稳健性,如果需要更精确的骨区域,可以回溯使用。